Guanfacine Tablet, Extended Release
Product Images NDC 60760-863

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 60760-863). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

863-.30 (Guanfacine 60760 863 30)

Guanfacine Extended-Release Tablets, USP 1 mg in a package of 30 tablets. The label includes the NDC 60760-863-30, is manufactured by Alembic Pharmaceuticals Limited, India, and packaged by St. Mary's Medical Park Pharmacy, Arizona. The label contains dosage form, strength, barcodes, and storage instructions at controlled room temperature.*

FDA Label Image

Figure2 (Guanfacine 2figure)

A scatter plot chart showing the fold change and 90% confidence intervals in pharmacokinetic parameters Cmax and AUC for guanfacine when affected by various CYP3A4/5 inhibitors and inducers, including ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate. The x-axis represents the change relative to reference on a scale from 0 to 5.*

FDA Label Image

Figure 3 (Guanfacine 3 Figure)

A pharmacokinetic chart showing the fold change and 90% confidence interval of Cmax and AUC for Oral Methylphenidate and Lisdexamfetamine Dimesylate as interacting drugs. The horizontal axis represents change relative to reference from 0 to 2, with most data points clustered near a fold change of 1.*

FDA Label Image

Figure1 (Guanfacine Figure 1)

A line graph comparing the plasma concentration of Guanfacine (ng/mL) over 24 hours for extended-release and immediate-release formulations, both at 1 mg once daily. The x-axis represents time in hours, and the y-axis shows Guanfacine plasma concentration. The graph distinguishes extended-release with square markers and immediate-release with triangle markers.*

FDA Label Image

Figure 4 (Guanfacine Figure4)

A Kaplan-Meier curve graph showing Treatment Failure (%) over Time to Treatment Failure (Days) for two groups: one receiving Placebo and the other SPD503. The graph illustrates different rates of treatment failure between the two groups over a period extending to approximately 200 days.*

FDA Label Image

Structure (Guanfacine Str)

Chemical structure of guanfacine hydrochloride, showing the molecular arrangement including chlorine atoms, amine groups, and the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.